Edecrin (Ethacrynic Acid)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Edecrin (Ethacrynic Acid)

EDECRIN®
(ethcynic acid) Tablets

SODIUM EDECRIN® (ethacrynic acid)
(ethacrynate sodium) Intravenous

EDECRIN* (Ethacrynic Acid) is a potent diuretic which, if given in excessive amounts, may lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION).

DRUG DESCRIPTION

Ethacrynic acid is an unsaturated ketone derivative of an aryloxyacetic acid. It is designated chemically as [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy] acetic acid, and has a molecular weight of 303.14. Ethacrynic acid is a white, or practically white, crystalline powder, very slightly soluble in water, but soluble in most organic solvents such as alcohols, chloroform, and benzene.

Its empirical formula is C13H12Cl2O4 and its structural formula is:

EDECRIN* (Ethacrynic Acid) Structural Formula Illustration

Ethacrynate sodium, the sodium salt of ethacrynic acid, is soluble in water at 25°C to the extent of about 7 percent. Solutions of the sodium salt are relatively stable at about pH 7 at room temperature for short periods, but as the pH or temperature increases the solutions are less stable. The molecular weight of ethacrynate sodium is 325.12. Its empirical formula is C13H11Cl2NaO4 and its structural formula is:

EDECRIN®(Ethacrynate sodium) Structural Formula Illustration

EDECRIN (ethacrynic acid) is supplied as 25 mg tablets for oral use. The tablets contain the following inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, starch and talc. Intravenous SODIUM EDECRIN (ethacrynic acid) * (Ethacrynate Sodium) is a sterile freeze-dried powder and is supplied in a vial containing:

Ethacrynate sodium equivalent to ethacrynic acid..................50.0 mg

Inactive ingredient:

Mannitol......................62.5 mg

What are the possible side effects of ethacrynic acid

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using ethacrynic acid and call your doctor at once if you have any of these serious side effects:

  • dry mouth, thirst, nausea, vomiting;
  • feeling weak, drowsy, restless, or light-headed;
  • fast or uneven heartbeat;
  • muscle pain or weakness;
  • easy bruising or bleeding, unusual weakness;
  • fever, chills, body aches, flu symptoms;
  • severe or watery diarrhea;
  • blood in...

Read All Potential Side Effects and See Pictures of Edecrin »

What are the precautions when taking ethacrynic acid (Edecrin)?

Before taking ethacrynic acid, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: severe watery diarrhea, very low blood pressure, severe kidney disease (making little or no urine), severe loss of water or minerals (e.g., dehydration, low potassium/sodium).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: blood clots (e.g., in the lungs, legs), diabetes, gout, kidney disease, liver disease...

Read All Potential Precautions of Edecrin »

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

EDECRIN (ethacrynic acid) is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.

  1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
  2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
  3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.
  4. Intravenous SODIUM EDECRIN (ethacrynic acid) is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.

DOSAGE AND ADMINISTRATION

Dosage must be regulated carefully to prevent a more rapid or substantial loss of fluid or electrolyte than is indicated or necessary. The magnitude of diuresis and natriuresis is largely dependent on the degree of fluid accumulation present in the patient. Similarly, the extent of potassium excretion is determined in large measure by the presence and magnitude of aldosteronism.

Oral Use

EDECRIN (ethacrynic acid) is available for oral use as 25 mg tablets.

Dosage: To Initiate Diuresis

In Adults: The smallest dose required to produce gradual weight loss (about 1 to 2 pounds per day) is recommended. Onset of diuresis usually occurs at 50 to 100 mg for adults. After diuresis has been achieved, the minimally effective dose (usually from 50 to 200 mg daily) may be given on a continuous or intermittent dosage schedule. Dosage adjustments are usually in 25 to 50 mg increments to avoid derangement of water and electrolyte excretion.

The patient should be weighed under standard conditions before and during the institution of diuretic therapy with this compound. Small alterations in dose should effectively prevent a massive diuretic response. The following schedule may be helpful in determining the smallest effective dose.

Day 1 - 50 mg once daily after a meal
Day 2 - 50 mg twice daily after meals, if necessary
Day 3 - 100 mg in the morning and 50 to 100 mg following the afternoon or evening meal, depending upon response to the morning dose.

A few patients may require initial and maintenance doses as high as 200 mg twice daily. These higher doses, which should be achieved gradually, are most often required in patients with severe, refractory edema.

In Pediatric Patients (excluding infants, see CONTRAINDICATIONS): The initial dose should be 25 mg. Careful stepwise increments in dosage of 25 mg should be made to achieve effective maintenance.

Maintenance Therapy

It is usually possible to reduce the dosage and frequency of administration once dry weight has been achieved.

EDECRIN (Ethacrynic Acid) may be given intermittently after an effective diuresis is obtained with the regimen outlined above. Dosage may be on an alternate daily schedule or more prolonged periods of diuretic therapy may be interspersed with rest periods. Such an intermittent dosage schedule allows time for correction of any electrolyte imbalance and may provide a more efficient diuretic response.

The chloruretic effect of this agent may give rise to retention of bicarbonate and a metabolic alkalosis. This may be corrected by giving chloride (ammonium chloride or arginine chloride). Ammonium chloride should not be given to cirrhotic patients.

EDECRIN (ethacrynic acid) has additive effects when used with other diuretics. For example, a patient who is on maintenance dosage of an oral diuretic may require additional intermittent diuretic therapy, such as an organomercurial, for the maintenance of basal weight. The intermittent use of EDECRIN (ethacrynic acid) orally may eliminate the need for injections of organomercurials. Small doses of EDECRIN (ethacrynic acid) may be added to existing diuretic regimens to maintain basal weight. This drug may potentiate the action of carbonic anhydrase inhibitors, with augmentation of natriuresis and kaliuresis. Therefore, when adding EDECRIN (ethacrynic acid) the initial dose and changes of dose should be in 25 mg increments, to avoid electrolyte depletion. Rarely, patients who failed to respond to ethacrynic acid have responded to older established agents.

While many patients do not require supplemental potassium, the use of potassium chloride or potassium-sparing agents, or both, during treatment with EDECRIN (ethacrynic acid) is advisable, especially in cirrhotic or nephrotic patients and in patients receiving digitalis.

Salt liberalization usually prevents the development of hyponatremia and hypochloremia. During treatment with EDECRIN (ethacrynic acid) , salt may be liberalized to a greater extent than with other diuretics. Cirrhotic patients, however, usually require at least moderate salt restriction concomitant with diuretic therapy.

Intravenous Use

Intravenous SODIUM EDECRIN (ethacrynic acid) is for intravenous use when oral intake is impractical or in urgent conditions, such as acute pulmonary edema.

The usual intravenous dose for the average sized adult is 50 mg, or 0.5 to 1.0 mg per kg of body weight. Usually only one dose has been necessary; occasionally a second dose at a new injection site, to avoid possible thrombophlebitis, may be required. A single intravenous dose not exceeding 100 mg has been used in critical situations.

Insufficient pediatric experience precludes recommendation for this age group.

To reconstitute the dry material, add 50 mL of 5 percent Dextrose Injection, or Sodium Chloride Injection to the vial. Occasionally, some 5 percent Dextrose Injection solutions may have a low pH (below 5). The resulting solution with such a diluent may be hazy or opalescent. Intravenous use of such a solution is not recommended. Inspect the vial containing Intravenous SODIUM EDECRIN (ethacrynic acid) for particulate matter and discoloration before use.

The solution may be given slowly through the tubing of a running infusion or by direct intravenous injection over a period of several minutes. Do not mix this solution with whole blood or its derivatives. Discard unused reconstituted solution after 24 hours.

SODIUM EDECRIN (ethacrynic acid) should not be given subcutaneously or intramuscularly because of local pain and irritation.

HOW SUPPLIED

Tablets EDECRIN (ethacrynic acid) , 25 mg, are white, capsule shaped, scored tablets, coded MSD 65 on one side and EDECRIN (ethacrynic acid) on the other. They are supplied as follows:

NDC 25010-205-15 in bottles of 100.

Intravenous SODIUM EDECRIN (ethacrynic acid) is a dry white material either in a plug form or as a powder. It is supplied in vials containing ethacrynate sodium equivalent to 50 mg of ethacrynic acid,

NDC 25010-210-27.

Storage

Store in a tightly closed container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Distributed by: Aton Pharma, Lawrenceville, NJ 08648, USA . Tablets EDECRIN® (Ethacrynic Acid) manufactured for: Aton Pharma, Inc. Lawrenceville, NJ 08648, USA by: Merck and Co., Inc. West Point PA 19486 USA. Intravenous SODIUM EDECRIN® (ethacrynic acid) (Ethacrynate Sodium) manufactured for: Aton Pharma, Inc. Lawrenceville, NJ 08648, USA by: DSM Pharmaceuticals, Inc. Greenville, NC 27835, USA. Issued October 2007. FDA Rev date: 2/9/2005

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

Gastrointestinal

Anorexia, malaise, abdominal discomfort or pain, dysphagia, nausea, vomiting, and diarrhea have occurred. These are more frequent with large doses or after one to three months of continuous therapy. A few patients have had sudden onset of profuse, watery diarrhea. Discontinue EDECRIN (ethacrynic acid) if diarrhea is severe and do not give it again. Gastrointestinal bleeding has occurred in some patients. Rarely, acute pancreatitis has been reported.

Metabolic

Reversible hyperuricemia and acute gout have been reported. Acute symptomatic hypoglycemia with convulsions occurred in two uremic patients who received doses above those recommended. Hyperglycemia has been reported. Rarely, jaundice and abnormal liver function tests have been reported in seriously ill patients receiving multiple drug therapy, including EDECRIN (ethacrynic acid) .

Hematologic

Agranulocytosis or severe neutropenia has been reported in a few critically ill patients also receiving agents known to produce this effect. Thrombocytopenia has been reported rarely.

Henoch-Schönlein purpura has been reported rarely in patients with rheumatic heart disease receiving multiple drug therapy, including EDECRIN (ethacrynic acid) .

Special Senses (see WARNINGS)

Deafness, tinnitus and vertigo with a sense of fullness in the ears, and blurred vision have occurred.

Central Nervous System

Headache, fatigue, apprehension, confusion.

Miscellaneous

Skin rash, fever, chills, hematuria.

SODIUM EDECRIN (ethacrynic acid) occasionally has caused local irritation and pain after intravenous use.

Read the Edecrin (ethacrynic acid) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy.

EDECRIN (ethacrynic acid) may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. Their concurrent use should be avoided.

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when EDECRIN (ethacrynic acid) and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

The effects of EDECRIN (ethacrynic acid) on electrolytes are related to its renal pharmacologic activity and are dose dependent. The possibility of profound electrolyte and water loss may be avoided by weighing the patient throughout the treatment period, by careful adjustment of dosage, by initiating treatment with small doses, and by using the drug on an intermittent schedule when possible. When excessive diuresis occurs, the drug should be withdrawn until homeostasis is restored. When excessive electrolyte loss occurs, the dosage should be reduced or the drug temporarily withdrawn.

Initiation of diuretic therapy with EDECRIN (ethacrynic acid) in the cirrhotic patient with ascites is best carried out in the hospital. When maintenance therapy has been established, the individual can be satisfactorily followed as an outpatient.

EDECRIN (ethacrynic acid) should be given with caution to patients with advanced cirrhosis of the liver, particularly those with a history of previous episodes of electrolyte imbalance or hepatic encephalopathy. Like other diuretics it may precipitate hepatic coma and death.

Too vigorous a diuresis, as evidenced by rapid and excessive weight loss, may induce an acute hypotensive episode. In elderly cardiac patients, rapid contraction of plasma volume and the resultant hemoconcentration should be avoided to prevent the development of thromboembolic episodes, such as cerebral vascular thromboses and pulmonary emboli which may be fatal. Excessive loss of potassium in patients receiving digitalis glycosides may precipitate digitalis toxicity. Care should also be exercised in patients receiving potassium-depleting steroids.

A number of possibly drug-related deaths have occurred in critically ill patients refractory to other diuretics. These generally have fallen into two categories: (1) patients with severe myocardial disease who have been receiving digitalis and presumably developed acute hypokalemia with fatal arrhythmia; (2) patients with severely decompensated hepatic cirrhosis with ascites, with or without accompanying encephalopathy, who were in electrolyte imbalance and died because of intensification of the electrolyte defect.

Deafness, tinnitus, and vertigo with a sense of fullness in the ears have occurred, most frequently in patients with severe impairment of renal function. These symptoms have been associated most often with intravenous administration and with doses in excess of those recommended. The deafness has usually been reversible and of short duration (one to 24 hours). However, in some patients the hearing loss has been permanent. A number of these patients were also receiving drugs known to be ototoxic. EDECRIN (ethacrynic acid) may increase the ototoxic potential of other drugs (see PRECAUTIONS: DRUG INTERACTIONS).

Lithium generally should not be given with diuretics (see PRECAUTIONS: DRUG INTERACTIONS).

PRECAUTIONS

General

Weakness, muscle cramps, paresthesias, thirst, anorexia, and signs of hyponatremia, hypokalemia, and/or hypochloremic alkalosis may occur following vigorous or excessive diuresis and these may be accentuated by rigid salt restriction. Rarely, tetany has been reported following vigorous diuresis. During therapy with ethacrynic acid, liberalization of salt intake and supplementary potassium chloride are often necessary.

When a metabolic alkalosis may be anticipated, e.g., in cirrhosis with ascites, the use of potassium chloride or a potassium-sparing agent before and during therapy with EDECRIN (ethacrynic acid) may mitigate or prevent the hypokalemia.

Loop diuretics have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia.

The safety and efficacy of ethacrynic acid in hypertension have not been established. However, the dosage of coadministered antihypertensive agents may require adjustment.

Orthostatic hypotension may occur in patients receiving other antihypertensive agents when given ethacrynic acid.

EDECRIN (ethacrynic acid) has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. A transient increase in serum urea nitrogen may occur. Usually, this is readily reversible when the drug is discontinued.

As with other diuretics used in the treatment of renal edema, hypoproteinemia may reduce responsiveness to ethacrynic acid and the use of salt-poor albumin should be considered.

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.

EDECRIN (ethacrynic acid) may increase the risk of gastric hemorrhage associated with corticosteroid treatment.

Laboratory Tests

Frequent serum electrolyte, CO2 and BUN determinations should be performed early in therapy and periodically thereafter during active diuresis. Any electrolyte abnormalities should be corrected or the drug temporarily withdrawn.

Increases in blood glucose and alterations in glucose tolerance tests have been observed in patients receiving EDECRIN (ethacrynic acid) .

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of a tumorigenic effect in a 79-week oral chronic toxicity study in rats at doses up to 45 times the human dose. Ethacrynic acid had no effect on fertility in a two-litter study in rats or a two-generation study in mice at 10 times the human dose.

Pregnancy

Pregnancy Category B: Reproduction studies in the mouse and rabbit at doses up to 50 times the human dose showed no evidence of external abnormalities of the fetus due to EDECRIN (ethacrynic acid) .

In a two-litter study in the dog and rat, oral doses of 5 or 20 mg/kg/day (2½ or 10 times the human dose), respectively, did not interfere with pregnancy or with growth and development of the pups. Although there was reduction in the mean body weights of the fetuses in a teratogenic study in the rat at a dose level of 100 mg/kg (50 times the human dose), there was no effect on mortality or postnatal development. Functional and morphologic abnormalities were not observed.

There are, however, no adequate and well-controlled studies in pregnant women. Since animal reproduction studies are not always predictive of human response, EDECRIN (ethacrynic acid) should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from EDECRIN (ethacrynic acid) , a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

There are no well-controlled clinical trials in pediatric patients. The information on oral dosing in pediatric patients, other than infants, is supported by evidence from empiric use in this age group. For information on oral use in pediatric patients, other than infants, see INDICATIONS and DOSAGE AND ADMINISTRATION.

Safety and effectiveness of oral and parenteral use in infants have not been established (see CONTRAINDICATIONS).

Safety and effectiveness of intravenous use in pediatric patients have not been established (see DOSAGE AND ADMINISTRATION, Intravenous Use).

Geriatric Use

Of the total number of subjects in clinical studies of EDECRIN (ethacrynic acid) /SODIUM EDECRIN (ethacrynic acid) , approximately 224 patients (21%) were 65 to 74 years of age, while approximately 100 patients (9%) were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. (See WARNINGS.)

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CONTRAINDICATIONS.)

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

Overdosage may lead to excessive diuresis with electrolyte depletion and dehydration.

In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma, and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.

In the mouse, the oral LD50 of ethacrynic acid is 627 mg/kg and the intravenous LD50 of ethacrynate sodium is 175 mg/kg.

CONTRAINDICATIONS

All diuretics, including ethacrynic acid, are contraindicated in anuria. If increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued.

In a few patients this diuretic has produced severe, watery diarrhea. If this occurs, it should be discontinued and not used again.

Until further experience in infants is accumulated, therapy with oral and parenteral EDECRIN (ethacrynic acid) is contraindicated.

Hypersensitivity to any component of this product.

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Pharmacokinetics and Metabolism

EDECRIN (ethacrynic acid) acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since EDECRIN (ethacrynic acid) inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, EDECRIN (ethacrynic acid) is effective in many patients who have significant degrees of renal insufficiency (see WARNINGS concerning deafness). EDECRIN (ethacrynic acid) has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.

The electrolyte excretion pattern of ethacrynic acid varies from that of the thiazides and mercurial diuretics. Initial sodium and chloride excretion is usually substantial and chloride loss exceeds that of sodium. With prolonged administration, chloride excretion declines, and potassium and hydrogen ion excretion may increase. EDECRIN (ethacrynic acid) is effective whether or not there is clinical acidosis or alkalosis.

Although EDECRIN (ethacrynic acid) , in carefully controlled studies in animals and experimental subjects, produces a more favorable sodium/potassium excretion ratio than the thiazides, in patients with increased diuresis excessive amounts of potassium may be excreted.

Onset of action is rapid, usually within 30 minutes after an oral dose of EDECRIN (ethacrynic acid) or within 5 minutes after an intravenous injection of SODIUM EDECRIN (ethacrynic acid) . After oral use, diuresis peaks in about 2 hours and lasts about 6 to 8 hours.

The sulfhydryl binding propensity of ethacrynic acid differs somewhat from that of the organomercurials. Its mode of action is not by carbonic anhydrase inhibition.

Ethacrynic acid does not cross the blood-brain barrier.

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Edecrin Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

ETHACRYNIC ACID - ORAL

(eth-a-KRIN-ik AS-id)

COMMON BRAND NAME(S): Edecrin

USES: Ethacrynic acid is a "water pill" (diuretic) that increases the amount of urine you make. This helps your body get rid of extra water. This medication decreases swelling/fluid retention (edema) caused by conditions such as cancer, congestive heart failure, liver disease, and kidney disease. This effect can help improve symptoms such as trouble breathing and swollen belly (ascites) and improve kidney function.

This medication should not be used in infants.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This drug may be used to treat high blood pressure in people who are allergic to other "water pills"/diuretics.

HOW TO USE: Take this medication by mouth, usually once or twice a day after a meal or as directed by your doctor.

It is best to avoid taking this medication within 4 hours of your bedtime to avoid having to get up to urinate. Consult your doctor or pharmacist if you have questions about your dosing schedule.

The dosage is based on your condition and response to therapy. Your doctor may start you on a low dose once a day and then gradually increase the dose. Your doctor will adjust your dose based on changes in your weight, how much swelling (edema) you have, and your lab test results (sodium, potassium, acid/base). Your doctor may stop the drug or lower the dose after most of the extra water is gone. Some people may take this medication every other day or occasionally when needed. Follow your doctor's directions carefully.

Take this medication regularly in order to get the most benefit from it. To help you remember, take it at the same time(s) each day.

Inform your doctor if your condition persists or worsens.

Disclaimer

Edecrin Consumer (continued)

SIDE EFFECTS: Dizziness, lightheadedness, headache, blurred vision, stomach upset, mild weakness/tiredness, or diarrhea may occur. This medication will cause an increase in the amount of urine. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

This drug is a strong "water pill" (diuretic). Using too much of this drug can lead to serious water and mineral loss (dehydration). Tell your doctor immediately if you have any of these unlikely but serious symptoms of dehydration: loss of appetite, confusion, severe dizziness/fainting, unusual dry mouth/thirst, severe headache, fast/irregular heartbeat, muscle cramps/spasms, nausea/vomiting, numbness/tingling, seizure, decrease in amount of urine, unusual weakness/tiredness.

Tell your doctor immediately if any of these rare but very serious side effects occur: easy bleeding/bruising, black/bloody stools, severe watery diarrhea, signs of infection (e.g., fever, persistent sore throat), ringing in the ear, feeling of spinning (vertigo), hearing loss, mental/mood changes (e.g., extreme sleepiness), pain/redness/new swelling of arms/legs, stomach/abdominal pain, large change in the amount of urine, dark urine, vomit that looks like coffee grounds, yellowing eyes/skin.

Seek immediate medical attention if any of these rare but very serious side effects occur: chest pain, weakness on one side of the body, slurred speech, vision changes.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Edecrin (ethacrynic acid) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before taking ethacrynic acid, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: severe watery diarrhea, very low blood pressure, severe kidney disease (making little or no urine), severe loss of water or minerals (e.g., dehydration, low potassium/sodium).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: blood clots (e.g., in the lungs, legs), diabetes, gout, kidney disease, liver disease (especially with cirrhosis or encephalopathy), peptic ulcer disease, stroke.

This drug may make you dizzy or drowsy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Avoid alcoholic beverages.

To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.

This drug can lower potassium/sodium levels in your blood. Your doctor may order you to increase your salt intake or eat foods high in potassium. Carefully follow the diet prescribed by your doctor. Do not change your salt intake without talking with your doctor first. A potassium supplement may be prescribed by your doctor.

Before having surgery, tell your doctor or dentist that you are taking this medication.

If you have diabetes, this medication may make it more difficult to control your blood sugar levels. Check your blood sugar regularly as directed by your doctor. Inform your doctor of the results.

Kidney function declines as you grow older. This medication is removed by the kidneys. Therefore, elderly people may be at greater risk for side effects while using this drug, especially dehydration.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Disclaimer

Edecrin Consumer (continued)

DRUG INTERACTIONS: Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.

This drug should not be used with the following medications because a very serious interaction may occur: cisapride, furosemide.

If you are currently using any of the medications listed above, tell your doctor or pharmacist before starting ethacrynic acid.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: other drugs that may affect hearing/balance such as aminoglycoside antibiotics (e.g., gentamicin, tobramycin), drugs that may lower potassium levels (e.g., amphotericin B, corticosteroids such as prednisone), digoxin, ginseng, high blood pressure medications, lithium, drugs for gout (uricosurics such as probenecid, sulfinpyrazone), warfarin.

Check the labels on all your medicines (such as cough-and-cold products, diet aids, or NSAIDs such as ibuprofen, naproxen) because they may contain ingredients that could increase your blood pressure or worsen your heart failure. Ask your pharmacist for more details.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others.

Laboratory and/or medical tests (e.g., complete blood count, blood minerals/carbon dioxide levels, kidney tests) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at room temperature at 77 degrees F (25 degrees C) away from light and moisture. Brief storage between 59-86 degrees F (15-30 degrees C) is permitted. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Information last revised March 2012. Copyright(c) 2012 First Databank, Inc.

Edecrin Patient Information Including Side Effects

Brand Names: Edecrin

Generic Name: ethacrynic acid (Pronunciation: eth a KRIN ik AS id)

What is ethacrynic acid (Edecrin)?

Ethacrynic acid is a loop diuretic (water pill) that prevents your body from absorbing too much salt, allowing the salt to instead be passed in your urine.

Ethacrynic acid treats fluid retention (edema) in people with congestive heart failure, liver disease, or a kidney disorder such as nephrotic syndrome.

Ethacrynic acid may also be used for other purposes not listed in this medication guide.

Edecrin 50 mg

oblong, green, imprinted with EDECRIN, MSD 90

What are the possible side effects of ethacrynic acid

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using ethacrynic acid and call your doctor at once if you have any of these serious side effects:

  • dry mouth, thirst, nausea, vomiting;
  • feeling weak, drowsy, restless, or light-headed;
  • fast or uneven heartbeat;
  • muscle pain or weakness;
  • easy bruising or bleeding, unusual weakness;
  • fever, chills, body aches, flu symptoms;
  • severe or watery diarrhea;
  • blood in your urine or stools;
  • coughing up blood or vomit that looks like coffee grounds;
  • rapid weight loss;
  • hearing loss, feeling of fullness in the ear; or
  • jaundice (yellowing of the skin or eyes).

Less serious side effects may include:

  • mild diarrhea, stomach pain, loss of appetite;
  • trouble swallowing;
  • headache; or
  • dizziness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Edecrin (ethacrynic acid) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about ethacrynic acid (Edecrin)?

Do not use this medication if you are unable to urinate, or if you have recently had severe watery diarrhea.

Before using this medication, tell your doctor if you have kidney disease, liver disease, or gout.

To be sure this medication is not causing harmful effects, your blood and your weight will need to be checked on a regular basis. Your kidney or liver function may also need to be tested. It is important that you not miss any scheduled visits to your doctor.

Ethacrynic acid will make you urinate more often and you may get dehydrated easily. Follow your doctor's instructions about using potassium supplements or getting enough salt and potassium in your diet.

Avoid becoming dehydrated. Follow your doctor's instructions about the type and amount of liquids you should drink while you are taking ethacrynic acid.

There are many other medicines that can interact with ethacrynic acid. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor. Keep a list with you of all the medicines you use and show this list to any doctor or other healthcare provider who treats you.

Side Effects Centers

Edecrin Patient Information including How Should I Take

What should I discuss with my healthcare provider before taking ethacrynic acid (Edecrin)?

Do not use this medication if you are unable to urinate, or if you have recently had severe watery diarrhea.

If you have any of these other conditions, you may need a dose adjustment or special tests to safely take ethacrynic acid:

  • kidney disease;
  • liver disease; or
  • gout.

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known whether ethacrynic acid passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take ethacrynic acid (Edecrin)?

Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.

Your doctor may occasionally change your dose to make sure you get the best results from this medication.

Take this medication with food unless your doctor tells you otherwise.

Ethacrynic acid will make you urinate more often and you may get dehydrated easily. Follow your doctor's instructions about using potassium supplements or getting enough salt and potassium in your diet.

To be sure this medication is not causing harmful effects, your blood and your weight will need to be checked on a regular basis. Your kidney or liver function may also need to be tested. Do not miss any scheduled appointments.

Store this medication at room temperature away from heat, light, and moisture.

Side Effects Centers

Edecrin Patient Information including If I Miss a Dose

What happens if I miss a dose (Edecrin)?

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Edecrin)?

Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include ringing in your ears, loss of appetite, weakness, dizziness, confusion, feeling light-headed, or fainting.

What should I avoid while taking ethacrynic acid (Edecrin)?

Avoid becoming dehydrated. Follow your doctor's instructions about the type and amount of liquids you should drink while you are taking ethacrynic acid.

What other drugs will affect ethacrynic acid (Edecrin)?

Before taking this medication, tell your doctor if you are using any of the following drugs:

  • lithium;
  • digoxin (Lanoxin);
  • a blood thinner such as warfarin (Coumadin);
  • other diuretics, especially furosemide (Lasix) or torsemide (Demadex);
  • blood pressure medicines;
  • steroids (prednisone and others);
  • cancer medicine such as cisplatin (Platinol), carboplatin (Paraplatin), or oxiplatin (Eloxatin);
  • a cephalosporin antibiotic such as Ceclor, Ceftin, Duricef, Keflex, Omnicef, Spectracef, and others;
  • salicylates such as aspirin, Disalcid, Doan's Pills, Dolobid, Salflex, Tricosal, and others;
  • NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen (Motrin, Advil), diclofenac (Voltaren), indomethacin, naproxen (Aleve, Naprosyn), piroxicam (Feldene), nabumetone (Relafen), etodolac (Lodine), and others; or
  • amikacin (Amikin), gentamicin (Garamycin), netilmicin (Netromycin), streptomycin, tobramycin (Nebcin, Tobi).

This list is not complete and there may be other drugs that can interact with ethacrynic acid. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about ethacrynic acid.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 8.03. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com